On-site Poster Session Program

**Day 2: December 18 (Saturday) 2021 at 13:40-14:20**

**Room 4**

**On-Site Poster Session Group 1**

*Chair: Dr. Hirayuki Enomoto (Japan)*

13:40-13:45

#10027 Hepatoma-derived Growth Factor as a Potential Therapeutic Target for Hepatocellular Carcinoma

Dr. Hirayuki Enomoto (Japan)

13:45-13:50

#10034 Iron Chelator Deferasirox Alters Sorafenib-induced Programmed Cell Deaths of Hepatoma Cells

Dr. Wataru Jomen (Japan)

13:50-13:55

#10052 Combination Therapy with Lenvatinib and RFA for CPA Patients with HCC Exceeding up-to-7 Criteria

Dr. Kazushi Numata (Japan)

13:55-14:00

#10088 Examination of the Detectability of Spoke Wheel Pattern by Contrast Ultrasonography in FNH

Dr. Masahiro Ogawa (Japan)

14:00-14:05

#10011 Bezafibrate Treatment is Associated with Reduced Risk for Development of HCC in Patients with PBC

Dr. Atsushi Tanaka (Japan)

14:05-14:10

#10031 Safety of Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma

Dr. Hiroshi Numao (Japan)

**On-site Poster Session Group 2**

*Chair: Dr. Fumitaka Suzuki (Japan)*

13:40-13:45

#10010 Real Impact of Tumor Marker AFP and PIVKA-II in Detecting Very Small Hepatocellular Carcinoma

Dr. Akito Nozaki (Japan)

13:45-13:50

#10054 Circulating IGFBP-1 Provides Resistance to Molecular Targeted Agent in Hepatocellular Carcinoma

Dr. Hiroyuki Suzuki (Japan)

13:50-13:55

#10081 Relationship between Serum Kynurenine Level and Prognosis of Patients with Hepatocellular Carcinoma

Dr. Shigemune Bekki (Japan)

13:55-14:00

#10082 Measurement of Renal Vein and IVC in Patients with Cirrhotic Ascites and Congestive Liver

Dr. Masahiro Kaneko (Japan)

14:00-14:05

#10017 Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series

Dr. Naoki Matsumoto (Japan)
An Autopsy Case of Ruptured Hepatocellular Carcinoma Following Administration of Lenvatinib
Dr. Kumichika Uchida (Japan)

On-site Poster Session Group 3
Chair: Dr. Ryota Masuzaki (Japan)
13:40-13:45
#10083 A Case of Mortality from an Incidental Intrahepatic Cholangiocarcinoma with Severe Cholecystitis
Dr. Yoshie Kadota (Japan)
13:45-13:50
#10041 Laparoscopic Surgery could be Most Frequently Employ as a Treatment for HCC in SVR era
Dr. Shuntaro Obi (Japan)
13:50-13:55
#10044 ATZ+BEV Therapy can Control Disease Activity in Patients Who Do Not Respond to Lenvatinib
Dr. Shuntaro Obi (Japan)
13:55-14:00
#10038 Incidence of HCC is Quite Different Depending on the History of HCC; A Prospective Study by 600 SVRs
Dr. Shuntaro Obi (Japan)
14:00-14:05
#10039 Beware of Carcinogenesis Other Than HCC; A Prospective Study by 600 SVRs
Dr. Shuntaro Obi (Japan)
14:05-14:10
#10040 Risk Factors for Occurrence of HCC after DAA Therapy; A Prospective Study by 600 SVRs
Dr. Shuntaro Obi (Japan)
14:10-14:15
#10043 Is Liver Carcinogenesis after SVR IM or MC? By Analysis of Gene Profiles
Dr. Shuntaro Obi (Japan)

On-site Poster Session Group 4
Chair: Dr. Makiko Taniai (Japan)
13:40-13:45
#10021 Major Signaling Pathway in Hepatocellular Carcinoma and Drug-matched Variants
Dr. Kenji Amemiya (Japan)
13:45-13:50
#10065 Phenotypic and Genetic Features of Multiple Nodules in HCC Based on Tumor Evolutionary Trait
Dr. Yosuke Hirotsu (Japan)
13:50-13:55
#10019 Impact of Hepatectomy for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus
Dr. Shohei Komatsu (Japan)
13:55-14:00
#10084 Conversion Surgery for Advanced Hepatocellular Carcinoma after Lenvatinib, a Case Report
Dr. Kazuki Kato (Japan)
14:00-14:05  
#1007  TACE with Cisplatin Versus Epirubicin for Hepatocellular Carcinoma, a Randomised Controlled Trial  
Dr. Osamu Aramaki (Japan)

14:05-14:10  
#1007  Examination of the Effect of Embolization of Corona Enhancement Area on Local Tumor Recurrence  
Dr. Yukinobu Watanabe (Japan)

On-site Poster Session Group 5  
Chair: Dr. Shinpei Sato (Japan)

13:40-13:45  
#10085  Experience of Antiviral Therapy in Patients Co-infected with HIV and Hepatitis Virus  
Dr. Yuki Haga (Japan)

13:45-13:50  
#10036  Levocarnitine Suppresses Lenvatinib-related Sarcopenia in Hepatocellular Carcinoma Patients  
Dr. Hironao Okubo (Japan)

13:50-13:55  
#10025  Clinical Features of Systemic Treatment in Japan  
Dr. Takaaki Tanaka (Japan)

13:55-14:00  
#10022  Clinical Trend of Japanese Patients with HCC in Progression of Aging Society: Clinical Role of RFA  
Dr. Shota Izumi (Japan)

14:00-14:05  
#10037  Two Cases of RFA for HCC in the Caudate Lobe; an Emerging Technique with Using Guided Needle Under CT  
Dr. Sae Yumita (Japan)

14:05-14:10  
#10030  The Cancer Risk in PSC and Ulcerative Colitis from 26 Years Retrospective Cohort Study in Japan  
Dr. Takashi Taida (Japan)

On-site Poster Session Group 6  
Chair: Dr. Shintaro Yamazaki (Japan)

13:40-13:45  
#10053  Stereotactic Body Radiotherapy for Early-stage Hepatocellular Carcinoma: A Single-Center Experience  
Dr. Shunsuke Okuyama (Japan)

13:45-13:50  
#10014  Impact of Postoperative Complications on Survival of Hepatocellular Carcinoma Patients  
Dr. Hisashi Nakayama (Japan)

13:50-13:55  
#10028  Surgical Resection for Hepatocellular Carcinoma with Major Vascular Invasion  
Dr. Shintaro Yamazaki (Japan)

13:55-14:00  
#10032  Impact of Patient Age on Outcome after Resection for Hepatocellular carcinoma  
Dr. Masaharu Harada (Japan)
14:00-14:05
#10056  Transient High Transaminase Elevation Does Not Affect on Short Term Outcomes after Liver Resection  Dr. Yusuke Mitsuka (Japan)

14:05-14:10
#10003  Sex-related Differences in Predictors of HCC Incidence after DAA Therapy in Patients with HCV  Dr. Takao Watanabe (Japan)
#10001  FBL is the Hub Gene of Pulmonary Metastasis in Hepatocellular Carcinoma  
Dr. Wen-Rui Wu (China)

#10002  Everolimus Protect IRI Through the Effect of Treg  
Dr. Li Zhu (China)

#10013  Durability of SVR in GT3 and GT6 Patients Treated with SOF/VEL with/without RBV from China  
Dr. Huagang Xiong (China)

#10016  Clinical Characteristics and Survival Analysis of Patients with HCC after HBV Negative  
Dr. Hong Li (China)

#10018  Characteristics of Genomic Profile of Hepatocellular Carcinoma after Sustained Virologic Response  
Dr. Hiroshi Ohyama (Japan)

#10042  A Case of Primary Biliary Cholangitis Undergoing RFA for Liver Metastasis of Cervical Cancer  
Dr. Ken Nogami (Japan)

#10048  Development of Novel Therapeutic Agents for HCC by Suppressing Soluble MICA through ADAM9 Inhibition  
Dr. Keita Ogawa (Japan)

#10050  Impacts of EZH2 Inhibitor UNC1999 on Tumor and Tumor Microenvironment in Hepatocellular Carcinoma  
Dr. Junjie Ao (Japan)

#10051  Efficacy of Sorafenib and Radiotherapy vs Sorafenib/Radiotherapy Monotherapy: A Systematic Review  
Dr. Rivaldo S. Heriyanto (Indonesia)

#10055  The Effect of Glucosylceramide Synthase Inhibitor on Liver Fibrosis Regression  
Dr. Terunao Iwanaga (Japan)

#10057  Stereotactic Body Radiation Therapy for Early-stage Hepatocellular Carcinoma  
Dr. Shigeki Yano (Japan)

#10059  Combination Therapy for Multiple HCC with Tyrosine Kinase Inhibitor and Radiofrequency Ablation  
Dr. Keita Maki (Japan)

#10068  Macrotubecular Massive Feature in Tumor is Associated with a Higher Risk of the Recurrence of HCC  
Dr. Hyun Woong Lee (Korea)

#10071  Acidic Microenvironment Aggravates HIRI by Modulating M1-Polarization by PPAR-gama Signal  
Dr. Wei Ding (China)

#10072  Protection Mechanism of DDIT4 S-Nitrosylation in ROS  
Dr. Yunfei Duan (China)

#10074  Molecular Mechanism of CCL7 by BRG1 in Liver Injury  
Dr. Yunjie Lu (China)

#10075  Dynamic Gut Microbiome Affects the Efficacy of PD-1-based Immunotherapy in Hepatocellular Carcinoma  
Dr. Chan Xie (China)

#10086  Regorafenib for Taiwanese Patients with Unresectable HCC after Sorafenib Failure  
Dr. Ming-Lung Yu (Taiwan)

#10087  Education and information sharing method for the coming era in ablation  
Dr. Maki Tobari (Japan)

#10089  MWA vs. RFA in Intermediate Stage Hepatocellular Carcinoma: A Retro-prospective Study  
Dr. Diana Alcantara Babaran (Philippines)